Authors

Paul England, DPhil

Senior professional support lawyer

Read More

Matthew Royle, Ph.D.

Partner

Read More

Colin McCall

Partner

Read More
Authors

Paul England, DPhil

Senior professional support lawyer

Read More

Matthew Royle, Ph.D.

Partner

Read More

Colin McCall

Partner

Read More

27 September 2018

Synapse - law for life sciences - September 2018

This month on Synapse

Biosimilars – an overview of the route to market in the US and Europe

Taylor Wessing and Willkie Farr & Gallagher present the first of three webinars covering various aspects of market access for biosimilars. In this webinar they cover the basics of the regulatory system in the US and Europe; the history of approvals and launches in the US and Europe; and an overview of the "patent dance" under the BPCIA and contrast to the position in Europe.

Topical issues

New government code of conduct for data-driven technologies in the health and care

Colin McCall and Nick Harrison explain what is in the Department of Health and Social Care (DHSC) has published in its initial Code of Conduct for the use of data-driven technology in the health and care sectors.

Brexit and the life sciences sector: the UK Government’s offer to the EU

In the first of three articles about the possible outcomes of Brexit and what they mean for the life sciences sector, in particular the authorisation of medicines and medical devices, Tim Worden and Paul England examine the Government's 'Chequers' offer to the UK on a future relationship.

Brexit and the life sciences sector: what is the relevance of the transition (implementation) period

In the second of three articles about the possible outcomes of Brexit and what they mean for the life sciences sector, in particular the authorisation of medicines and medical devices, Paul England examines the relevance of the transition (implementation) period.

Brexit and the life sciences sector: guidelines for 'no deal'

In the final article about the possible outcomes of Brexit and what they mean for the life sciences sector, in particular the authorisation of medicines and medical devices, Matthew Royle and Paul England address the guidelines issued by the UK Government and EU Commission in the event of a ‘no deal’ Brexit.

Patents Court rules SPC invalid in Truvada

Paul England provides the latest on the Truvada supplementary protection certificate case in the UK.

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

EU and British cargo containers
Brexit

Brexit – what's the deal for business?

12 January 2021
Briefing

by multiple authors

Click here to find out more
Patterned pills
Life sciences & healthcare

8+2+1 plus what? How UK data and market exclusivity rights will be affected from 1 January 2021

3 December 2020
Briefing

by Alison Dennis and Paul England, DPhil

Click here to find out more
ring binders on cabinet
Patents & innovation

Reloaded: How UK supplementary protection certificates will change from 1 January 2021

24 November 2020
Briefing

by Paul England, DPhil

Click here to find out more